HIF1A and hepatocellular carcinoma: Different studies showed that sustained sorafenib therapy leads to increased intratumor hypoxia, which has been associated with reduced sorafenib sensitivity through HIF stabilization in HCC, and reported that targeting HIF-1α can improve sorafenib efficacy.